Please check your internet connection and try again.
# Meftal-Spas
## Overview
Meftal-Spas is a combination drug containing **Mefenamic Acid** (250 mg), a non-steroidal anti-inflammatory drug (NSAID), and **Dicyclomine Hydrochloride** (10 mg), an antispasmodic/anticholinergic agent.
## Primary Indications
* Management of spasmodic dysmenorrhea (primary menstrual pain).
* Symptomatic relief of gastrointestinal colicky pain or smooth muscle spasms.
## Adult Dosing
* **Standard Dose:** 1 tablet (250 mg Mefenamic Acid / 10 mg Dicyclomine) taken orally 3 to 4 times daily.
* **Maximum Dose:** Do not exceed 4 tablets in 24 hours. Limit total duration usually to 3–5 days for dysmenorrhea.
## Pediatric Dosing
* **Not recommended for children under 12 years of age.** Safety and efficacy have not been established for this specific combination in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** Avoid or exercise extreme caution in patients with severe renal impairment due to the Mefenamic Acid component.
* **Hepatic Impairment:** Use caution; Mefenamic Acid is extensively metabolized in the liver.
* **Elderly:** Use with caution; increased risk of anticholinergic side effects (confusion, urinary retention, constipation) from Dicyclomine and GI/renal risks from NSAIDs.
## Contraindications
* Hypersensitivity to Mefenamic Acid, Dicyclomine, or other NSAIDs.
* History of asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Obstructive uropathy or gastrointestinal obstruction.
* Severe ulcerative colitis or myasthenia gravis.
* Peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, diarrhea (Mefenamic Acid can cause significant diarrhea), abdominal pain.
* **Anticholinergic:** Dry mouth, blurred vision, tachycardia, urinary retention, constipation, dizziness, and confusion.
* **Systemic:** Increased risk of cardiovascular thrombotic events (myocardial infarction, stroke), hypertension, and peripheral edema.
## Key Drug Interactions
* **Anticoagulants (e.g., Warfarin):** Increased risk of bleeding.
* **Antiplatelets/SSRIs:** Increased gastrointestinal bleeding risk.
* **Other Anticholinergics:** Synergistic effects, increasing risk of dry mouth, urinary retention, and cognitive impairment.
* **Diuretics/ACE Inhibitors/ARBs:** Reduced antihypertensive effect and increased risk of acute renal failure.
* **Methotrexate:** Increased toxic plasma levels.
## Monitoring
* Monitor blood pressure periodically.
* Observe for signs/symptoms of GI ulceration or bleeding (melena, hematemesis).
* Monitor renal function (serum creatinine) with chronic or high-dose use.
* Assess for manifestations of anticholinergic toxicity (e.g., severe constipation, urinary retention).
## Clinical Pearls
* **Diarrhea Alert:** Mefenamic Acid is well-known to cause diarrhea; if it develops, the medication should be discontinued immediately.
* **Dicyclomine Limits:** Due to the anticholinergic profile, patients should be warned about sedation and potential impairment of motor skills (avoid driving if affected).
* **Avoid in Pregnancy:** Especially in the third trimester due to risk of premature closure of the ductus arteriosus.
* **Short Duration:** This medication is intended for acute, short-term symptom relief, not long-term chronic pain management.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug information, labeling, and local prescribing protocols are subject to change. Always verify the current prescribing information via official local databases, institutional guidelines, or product monographs before clinical use.
